Pfizer Inc. (NYSE:PFE) Shares Sold by Commerce Bank

Commerce Bank reduced its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 4.2% in the third quarter, according to its most recent filing with the SEC. The fund owned 2,092,752 shares of the biopharmaceutical company's stock after selling 91,538 shares during the period. Commerce Bank's holdings in Pfizer were worth $60,564,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. FAS Wealth Partners Inc. grew its stake in Pfizer by 1.3% during the 2nd quarter. FAS Wealth Partners Inc. now owns 26,306 shares of the biopharmaceutical company's stock worth $736,000 after buying an additional 342 shares during the last quarter. Sachetta LLC grew its position in shares of Pfizer by 7.3% in the second quarter. Sachetta LLC now owns 5,010 shares of the biopharmaceutical company's stock valued at $140,000 after purchasing an additional 342 shares in the last quarter. Wells Trecaso Financial Group LLC grew its position in Pfizer by 2.5% in the third quarter. Wells Trecaso Financial Group LLC now owns 14,361 shares of the biopharmaceutical company's stock worth $416,000 after acquiring an additional 350 shares during the period. Ironvine Capital Partners LLC grew its position in Pfizer by 2.1% in the first quarter. Ironvine Capital Partners LLC now owns 16,953 shares of the biopharmaceutical company's stock worth $470,000 after acquiring an additional 353 shares during the period. Finally, Secure Asset Management LLC grew its position in Pfizer by 0.6% in the second quarter. Secure Asset Management LLC now owns 58,328 shares of the biopharmaceutical company's stock worth $1,632,000 after acquiring an additional 353 shares during the period. 68.36% of the stock is owned by institutional investors.

Insider Activity at Pfizer

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of the stock in a transaction that occurred on Wednesday, October 30th. The shares were purchased at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the transaction, the director now directly owns 10,000 shares in the company, valued at $282,400. The trade was a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.06% of the stock is owned by insiders.

Analyst Ratings Changes

Several brokerages recently weighed in on PFE. Citigroup began coverage on Pfizer in a research report on Friday, October 25th. They issued a "neutral" rating and a $30.00 price objective for the company. Sanford C. Bernstein assumed coverage on Pfizer in a research note on Thursday, October 17th. They set a "market perform" rating and a $32.00 target price for the company. Barclays lifted their price target on Pfizer from $30.00 to $32.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 31st. Wolfe Research began coverage on Pfizer in a research report on Friday, November 15th. They set an "underperform" rating and a $25.00 price target on the stock. Finally, Daiwa America raised Pfizer from a "moderate buy" rating to a "strong-buy" rating in a report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $32.92.

Pfizer Stock Performance

NYSE:PFE traded down $0.25 during trading hours on Wednesday, reaching $24.85. 32,065,225 shares of the stock were exchanged, compared to its average volume of 38,382,414. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a 50 day simple moving average of $28.45 and a 200-day simple moving average of $28.63. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The stock has a market capitalization of $140.82 billion, a P/E ratio of 33.70, a P/E/G ratio of 0.79 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. The business had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business's revenue was up 31.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.17) EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.76%. The ex-dividend date is Friday, November 8th. Pfizer's dividend payout ratio is currently 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.